The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...

The FDA has approved ARS Pharmaceuticals’ neffy 1 mg, an epinephrine nasal spray, for type 1 allergic reactions, including anaphylaxis, in pediatric patients over four years of age who weigh between ...

Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in children aged 4 years and older weighing 15 to less than 30kg.

It's for adults, and for children who weigh at least 66 pounds, who have what are known as type 1 allergic reactions, which include the potentially life-threatening condition called anaphylaxis.

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 ...

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to 30 Kilograms ...

The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 ...

Morningstar brands and products Company Portfolio ...